invIOs

invIOs, formerly known as APEIRON Cell Therapies (a spin off of APEIRON Biologics and currently a subsidiary of invIOs Holding AG), is a biotech company focused on developing immunotherapies for the potential treatment of cancer.In December 2021, the company, a wholly owned subsidiary of APEIRON Biologics, had been assigned APEIRON's cancer immunotherapy activities and all related clinical and preclinical R&D projects. The company announced that it would commence operations on 1 January 2022. In April 2022, APEIRON Biologics announced that the new structure of the group had been approved through the demerger of its preclinical and clinical development activities and the creation of a new fully separate holding company, invIOs Holding AG. The shareholders in APEIRON Biologics would be granted shares in invIOs Holding AG pro rata to their current shareholdings in APEIRON Biologics. invIOs Holding AG would manage the operations of its wholly-owned subsidiaries invIOs and APEIRON Respiratory Therapi